Minimal Residual Disease (MRD) Negativity and Lenalidomide Maintainence Therapy are Associated with Superior Survival Outcomes in Multiple Myeloma

被引：0
|
作者：
Gopalakrishnan, Ragisha [1 ]
Engelhardt, Brian G. [1 ]
Sengsayedeth, Salyka [1 ]
Culos, Kathryn A. [2 ]
Byrne, Michael T. [3 ]
Goodman, Stacey [1 ]
Savani, Bipin N. [3 ]
Chinratanalab, Wichai [1 ]
Jagasia, Madan [4 ]
Cornell, Robert Frank [1 ]
Kassim, Adetola A. [3 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Vanderbilt Univ, Med Ctr, Pharm, Nashville, TN USA
[3] Vanderbilt Univ, Med Ctr, Hematol Oncol, Nashville, TN USA
[4] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2018年 / 24卷 / 03期
关键词：
D O I：
10.1016/j.bbmt.2017.12.660
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
77
引用
收藏
页码：S76 / S77
页数：2
相关论文
共 50 条
  • [21] Correlation of minimal residual disease negativity (MRD-) with prognosis in high-risk myeloma (HRM).
    Kunacheewa, Chutima
    Patel, Krina K.
    Lee, Hans Chulhee
    Thomas, Sheeba K.
    Amini, Behrang
    Srour, Samer
    Bashir, Qaiser
    Qazilbash, Muzaffar H.
    Weber, Donna M.
    Neelapu, Sattva Swarup
    Orlowski, Robert Z.
    Feng, Lei
    Lin, Pei
    Manasanch, Elisabet Esteve
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)
    Derman, Benjamin A.
    Major, Ajay
    Cooperrider, Jennifer
    Jiang, Ken
    Ramsland, Aubrianna
    Karrison, Theodore
    Kubicki, Tadeusz
    Jakubowiak, Andrzej J.
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [23] Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)
    Derman, Benjamin Avi
    Cooperrider, Jennifer H.
    Kubicki, Tadeusz
    Major, Ajay
    Jiang, Ken
    Ramsland, Aubrianna
    Buckley, Karson
    Melka, Samrawit
    McIver, Amanda
    Karrison, Theodore
    Jakubowiak, Andrzej J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Serological normalisation as a surrogate marker for minimal residual disease negativity in multiple myeloma
    Campbell, Lauren
    Panitsas, Fotios
    Basu, Supratik
    Anyanwu, Francis
    Lee, Sophie
    Ferry, Berne
    Ramasamy, Karthik
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (04) : 775 - 778
  • [25] POINT Should minimal residual disease negativity be the end point of myeloma therapy?
    Anderson, Kenneth C.
    BLOOD ADVANCES, 2017, 1 (08) : 517 - 521
  • [26] Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients
    Mithraprabhu, Sridurga
    Reynolds, John
    Quach, Hang
    Horvath, Noemi
    Kerridge, Ian
    Khong, Tiffany
    Durie, Brian G. M.
    Spencer, Andrew
    HAEMATOLOGICA, 2024, 109 (03) : 974 - 978
  • [27] Minimal residual disease (mrd) in multiple myeloma: prognostic and therapeutic implications (including imaging)
    Owen, Roger G.
    HEMASPHERE, 2019, 3 : 124 - 126
  • [28] The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients
    Paiva, Bruno
    Cedena, Teresa
    Puig, Noemi
    Cordon, Lourdes
    Martinez-Lopez, Joaquin
    Ocio, Enrique M.
    Hernandez, Miguel T.
    Isabel Teruel, Ana
    Gironella, Mercedes
    Asuncion Echeveste, M.
    Rosinol, Laura
    Martinez, Rafael
    Oriol, Albert
    Martin, Jesus
    Gutierrez, Norma C.
    Belen Vidriales, Maria
    Blade, Joan
    Jose Lahuerta, Juan
    Mateos, Maria-Victoria
    San Miguel, Jesus
    BLOOD, 2015, 126 (23)
  • [29] Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
    Mohan, Meera
    Kendrick, Samantha
    Szabo, Aniko
    Yarlagadda, Naveen
    Atwal, Dinesh
    Pandey, Yadav
    Roy, Arya
    Parikh, Richa
    Lopez, James
    Thanendrarajan, Sharmilan
    Schinke, Carolina
    Alapat, Daisy
    Sawyer, Jeffrey
    Tian, Erming
    Tricot, Guido
    van Rhee, Frits
    Zangari, Maurizio
    BLOOD ADVANCES, 2022, 6 (03) : 808 - 817
  • [30] Achieving minimal residual disease (MRD) negativity in CLL is independently associated with improved progression-free and overall survival and is an appropriate end-point of therapy
    Kwok, M.
    Rawstron, A. C.
    Varghese, A.
    Hillmen, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 : 20 - 21
12345